← All trials
NCT06039384
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2024
- Primary completion
- Nov 3, 2025
- Completion date
- Nov 3, 2025
- First posted
- Sep 15, 2023
- Last posted
- Dec 1, 2023
- Enrollment
- 125
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IncyteLead sponsor
- IncyteStudy director
- Mirati Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.